CA24463V1013
© Newsfile
10.04.2023
DTC
LISTED
CSE
Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it successfully established a str...
Themefolio
Profiler
Peergroup
© Newsfile
28.03.2023
DTC
LISTED
CSE
Defence to Complete a Final Pre-Clinical Study Prior to IND Filings for the AccuTOX(TM) Phase I Cancer Trial at the City of Hope National Medical Center and Beckman Research Institute
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it is currently conducting a final...
Themefolio
Profiler
Peergroup
© Newsfile
17.03.2023
DTC
LISTED
CSE
Defence Therapeutics Announces Exercise of Warrants for Gross Proceeds of over $5 Million
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that over the course of the last 6 months the Company has received...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Newsfile
14.03.2023
DTC
LISTED
CSE
Defence Therapeutics Signs Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), is pleased to announce that it has signed a Collaboration Agreement with Orano Support SAS on behalf of Orano SA ("Orano"), a world-renowned multinational company, headquartered in Chatillo...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
27.02.2023
DTC
LISTED
CSE
Defence's Pipeline Advances to Multiple Phase I Clinical Trials
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to update its stakeholders on its complete...
Themefolio
Profiler
Peergroup
© Newsfile
21.02.2023
DTC
LISTED
CSE
Defence Delegates City of Hope to Initiate IND Filing for Its AccuTOX(TM) Cancer Program
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it signed an agreement with Cit...
Themefolio
Profiler
Peergroup
© Newsfile
06.02.2023
DTC
LISTED
CSE
RETRANSMISSION: Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufact...
Themefolio
Profiler
Peergroup
© Newsfile
03.02.2023
DTC
LISTED
CSE
Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufact...
Themefolio
Profiler
Peergroup
© Newsfile
02.02.2023
DTC
LISTED
CSE
Defence Therapeutics and CQDM Fund the Development of a New Cancer Vaccine Platform
News Preview
Montreal, Quebec--(Newsfile Corp. - February 2, 2023) - In celebration of World Cancer Day, Defence Therapeutics and CQDM are proud to announce the launch of a collaborative research project between Université de Montréal (UdeM), the Lady Davis Institute of the Jewish General Hospital and Defence Therapeutics, a Quebec-based biotechnology...
Themefolio
Profiler
Peergroup
© Newsfile
31.01.2023
DTC
LISTED
CSE
Defence's Lung Cancer GLP tox Study on Its Intranasal AccuTOX(TM) Formulation Advances
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 31, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its GLP studies on a new...
Themefolio
Profiler
Peergroup
© Newsfile
24.01.2023
DTC
LISTED
CSE
Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine cand...
Themefolio
Profiler
Peergroup
© Newsfile
23.01.2023
DTC
LISTED
CSE
RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from Febru...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
20.01.2023
DTC
LISTED
CSE
Defence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from Febru...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2023
DTC
LISTED
CSE
Defence Accum(TM) Accepted Us Patent to Bolster Its Vaccine Platform Technology IP
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is...
Themefolio
Profiler
Peergroup
© Newsfile
10.01.2023
DTC
LISTED
CSE
mRNA with Defence's Accum(TM) Program Has Been Initiated
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement in the development o...
Themefolio
Profiler
Peergroup
© Newsfile
20.12.2022
DTC
LISTED
CSE
Breakthrough Results: Defence's Novel AccuTOX(TM) Intranasal Reduced 50% of Cancer Nodules on Animals with Lung Tumors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, just completed a pre-clinical study using its intrana...
Themefolio
Profiler
Peergroup
© Newsfile
15.12.2022
DTC
LISTED
CSE
Defence's mRNA with Accum(TM) for Cancer Vaccines Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its AccumTM technology...
Themefolio
Profiler
Peergroup
© Newsfile
09.12.2022
DTC
LISTED
CSE
Defence Therapeutics Appoints Kwin Grauer to Its Board of Directors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the appointment of Mr. Kwin Gra...
Themefolio
Profiler
Peergroup
© Newsfile
06.12.2022
DTC
LISTED
CSE
Defence Positioned to Begin Its Anti-Cancer AccuTOX(TM) Phase I Trial with Successful Completion of GLP Studies
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 6, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP...
Themefolio
Profiler
Peergroup
© Newsfile
23.11.2022
DTC
LISTED
CSE
Defence's Successfull Study on the AccuVAC-PT007 Vaccine Targeting Cervical Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 23, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the successful completion...
Themefolio
Profiler
Peergroup
© Newsfile
17.11.2022
DTC
LISTED
CSE
Defence Therapeutics Completes Fully-Subscribed Debenture Financing of $2,355,000
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the closing of its previously annou...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2022
DTC
LISTED
CSE
BTV Features: Defence Therapeutics, Volatus Aerospace, NGEx Minerals, York Harbour Metals, & AuTECO Minerals
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2022) - On national TV Sat. November 12 & Sun. November 13, 2022 - BTV-Business Television showcases emerging companies in the markets.Cannot view this video? Visit:http://www.b-tv.com/post/btv-features-defence-therapeutics-volatus-aerospace-ngex-minerals-york-harbour-metals-auteco-mi...
Themefolio
Profiler
Peergroup
© Newsfile
31.10.2022
DTC
LISTED
CSE
mRNA Program: Defence to Apply Its Propriatry Accum(TM) Technology in The Design of Messenger RNA Anti-Cancer Vaccines
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is initiating a new research and development program design...
Themefolio
Profiler
Peergroup
© Newsfile
29.10.2022
DTC
LISTED
CSE
Defence Therapeutics Announces Debenture Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce a non-brokered private placement of...
Themefolio
Profiler
Peergroup
© Newsfile
12.10.2022
DTC
LISTED
CSE
Defence Therapeutics Initiates Lung Cancer Treatment Program with Its Novel AccuTOX(TM) Formulation via Intranasal
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 12, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the start of a pre-clinical program us...
Themefolio
Profiler
Peergroup
© Newsfile
29.09.2022
DTC
LISTED
CSE
Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), i...
Themefolio
Profiler
Peergroup
© Newsfile
21.09.2022
DTC
LISTED
CSE
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report that Defence's novel vaccine candida...
Themefolio
Profiler
Peergroup
© Newsfile
16.09.2022
DTC
LISTED
CSE
Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, congratulates the US President Joe Biden for the executive or...
Themefolio
Profiler
Peergroup
© Newsfile
17.08.2022
DTC
LISTED
CSE
Breakthrough Discovery: Defence's Accum(TM) Variant "A1" Converts Mesenchymal Stromal Cells into Potent Antigen Presenting Cells Suitable for Cancer Vaccination
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the development of a novel anti-cancer...
Themefolio
Profiler
Peergroup
© Newsfile
08.08.2022
DTC
LISTED
CSE
Defence Therapeutics Receives U.S. Patent Covering Its ADC Platform Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 8, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"),...
Themefolio
Profiler
Peergroup
© Newsfile
02.08.2022
DTC
LISTED
CSE
Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the discovery of a novel DNA damaging fu...
Themefolio
Profiler
Peergroup
© Newsfile
05.07.2022
DTC
LISTED
CSE
Defence's Accum(TM) with Antibody Drug Conjugates (ADC) in Development Against Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in developm...
Themefolio
Profiler
Peergroup
© Newsfile
27.06.2022
DTC
LISTED
CSE
Defence Reports Effective Control of Cervical Cancer Growth in Response to Its AccuVAC-PT007 Therapeutic Vaccination
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report potent pre-clinical results on the use of...
Themefolio
Profiler
Peergroup
© Newsfile
18.05.2022
DTC
LISTED
CSE
RETRANSMISSION: Defence's Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer
News Preview
The Company is issuing a clarification news release at the request of IIROC.Vancouver, British Columbia--(Newsfile Corp. - May 18, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focused on the development of novel immune-oncology vaccines and dr...
Themefolio
Profiler
Peergroup
© Newsfile
17.05.2022
DTC
LISTED
CSE
Defence Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of no...
Themefolio
Profiler
Peergroup
© Newsfile
07.04.2022
DTC
LISTED
CSE
Defence Therapeutics Announces Issuance Of a U.S. Patent Covering Its Pioneering Vaccine Platform Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 7, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company primarily focused on the development of novel vaccines and drug delivery technologies, is pleased to announced that the United States Patent and Trademar...
Themefolio
Profiler
Peergroup
© Newsfile
22.03.2022
DTC
LISTED
CSE
Defence Therapeutics: An Anti-Cancer Solutions Platform Company Advancing Its Versatile Accum Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF)("Defence" or the "Company"), a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, is pleased to provide an overview of its current research and deve...
Themefolio
Profiler
Peergroup
© Newsfile
28.02.2022
DTC
LISTED
CSE
Defence Releases Peer-Reviewed Publication of Its Preclinical Data on AccuVAC-D001L In Cell Reports Medicine Journal
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the publication of its first peer-reviewed study on the potency of...
Themefolio
Profiler
Peergroup
© Newsfile
16.02.2022
DTC
LISTED
CSE
Defence Retains CATO SMS to Advise on Its Phase I Clinical Trial on AccuTOX(TM) for Breast Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the establishment of an agreement with CATO SMS, to advise on the...
Themefolio
Profiler
Peergroup
© Newsfile
26.01.2022
DTC
LISTED
CSE
Defence's Accum(TM)-HPV Vaccine Formulation (AccuVAC-PT009) Activates a 36-Fold Higher Humoral Response Compared to Gardasil-9
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the development of AccuVAC-PT009, a new protein-based HPV vaccine, leading to a hu...
Themefolio
Profiler
Peergroup
© Newsfile
10.01.2022
DTC
LISTED
CSE
Defence Therapeutics Achieves a Major Milestone and Begins IND-Enabling Testing of Its AccuTOX Lead Compound Against Breast Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the start of its final step in GLP studies on its lead anti-cancer AccuTOXTM molec...
Themefolio
Profiler
Peergroup
© Newsfile
13.12.2021
DTC
LISTED
CSE
Defence Therapeutics Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of the CRISPR/Cas9 Protein to Target Cells
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company focused on the development of vaccines and therapeutics against cancer and infectious diseases, is pleased to announce that its AccumTM platform can potently enha...
Themefolio
Profiler
Peergroup
© Newsfile
30.11.2021
DTC
LISTED
CSE
Defence Therapeutics Vaccines and Program Development
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary Accu...
Themefolio
Profiler
Peergroup
© Newsfile
23.11.2021
DTC
LISTED
CSE
Defence Therapeutics Cancer Vaccine AccuVac-D001 Manufacturing Targets Melanoma and Breast Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 23, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the establishment of an agreement with the Lady Davis Institute cell process...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2021
DTC
LISTED
CSE
Defence Therapeutics Appoints Dr. Riam Shammaa to Its Board of Directors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on the development of next generation cancer therapeutics and infectious disease vaccines is pleased to announce the appointment of Dr. Riam Shammaa to its...
Themefolio
Profiler
Peergroup
© Newsfile
03.11.2021
DTC
LISTED
CSE
Defence Therapeutics Reports Successful Completion of Its COVID-19 Vaccine AccuVAC-PT001 Toxicology Studies in Rabbits
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2021) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a biotechnology company working on the development of next generation cancer therapeutics and infectious disease vaccines is pleased to announce the successful completion of its protein-b...
Themefolio
Profiler
Peergroup
© Newsfile
13.10.2021
DTC
LISTED
CSE
Defence Therapeutics Accum(TM) Variants in Vitro Study Increases the Potency of T-Deruxtecan ADC by 5-Fold on Breast Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce strong in vitro results of its AccumTM variants on the recent Enhertu® (...
Themefolio
Profiler
Peergroup
© Newsfile
06.10.2021
DTC
LISTED
CSE
Defence Therapeutics Prepares for Phase I Trial to Test Its DC Cancer Vaccine, AccuVAC-D002, Against Melanoma
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines, is finalizing all required steps in preparation to a pre-IND meeting to initiate a phase I trial aga...
Themefolio
Profiler
Peergroup
© Newsfile
29.09.2021
DTC
LISTED
CSE
Defence Therapeutics to Finalize Its Objectives to Initiate a Phase I Trial Against Breast Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology Company working on cancer therapeutics and infectious diseases vaccines, is pleased to announce that it will be conducting a series of final studies to complete all requ...
Themefolio
Profiler
Peergroup
© Newsfile
20.09.2021
DTC
LISTED
CSE
Defence Therapeutics Successfully Engineered and Tested a Novel Intranasal COVID-19 Vaccine Formulation in Animals
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the development of a "non-injectable" second generation COVID vaccine, Accu...
Themefolio
Profiler
Peergroup
© Newsfile
14.09.2021
DTC
LISTED
CSE
Defence Therapeutics Success in Testing Its COVID-19 AccuVAC-PT001 Vaccine in a Non-Rodent Model
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines, is pleased to announce the completion of a non-GLP study on rabbits demonstrating a potent humora...
Themefolio
Profiler
Peergroup
© Newsfile
07.09.2021
DTC
LISTED
CSE
Defence Therapeutics Development Program to Engineer a New HPV Vaccine Initiated
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its AccumTM technology and cancer vaccine therapeutics and infectious disease vaccines, is pleased to announ...
Themefolio
Profiler
Peergroup
© Newsfile
31.08.2021
DTC
LISTED
CSE
Defence Therapeutics Files Acid-Based Hydrogels USA Provisional Patent Application
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its AccumTM technology and cancer vaccine therapeutics and infectious disease vaccines is pleased to announce...
Themefolio
Profiler
Peergroup
© Newsfile
18.08.2021
DTC
LISTED
CSE
Defence Therapeutics Selects the Best Eight Accum(TM) Variants to Optimize Its ADC Therapeutic
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 18, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased to announce, that after a detailed and rigorous selection process, very strong and promising results of its bests AccumTM variants has been identified. Defence's has tested 43 AccumTM variants conjugated to...
Themefolio
Profiler
Peergroup
© Newsfile
11.08.2021
DTC
LISTED
CSE
Defence Therapeutics Receives DTC Eligibility
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 11, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines, is pleased to announce that the Company received its DTC eligibility. Defence's common shares are now eligible for book entry and...
Themefolio
Profiler
Peergroup
© Newsfile
04.08.2021
DTC
LISTED
CSE
Defence Therapeutics Signs an Agreement with Biopharma Excellence, a Pharmalex GmbH Company, to Maximize and Strategize the Development of Its Accum(TM) Platform and Clinical Trials
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the agreement with the German renowned pharmaceutical consulting and advisory company, Pharmalex GmbH, throu...
Themefolio
Profiler
Peergroup
© Newsfile
06.07.2021
DTC
LISTED
CSE
The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce, as an update of it's May 31st, 2021 press release, that sera isolated from AccuVAC-PT001-vaccinated animals c...
Themefolio
Profiler
Peergroup
© Newsfile
29.06.2021
DTC
LISTED
CSE
Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased to announce the establishment of a collaboration with the Curie Institute (Paris, France) to evaluate the therapeutic efficacy of Accum-T-DM1 ADC in patient-derived xenograft (PDX) models of breast cancer. Th...
Themefolio
Profiler
Peergroup
© Newsfile
22.06.2021
DTC
LISTED
CSE
Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased to announce major breakthrough advances in its pre-clinical research program on its AccuTOX (free AccumTM or AccumTM variants) molecules as potent anti-cancer agents. The AccumTM technology platform is very...
Themefolio
Profiler
Peergroup
© Newsfile
07.06.2021
DTC
LISTED
CSE
Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company") is pleased to announce, after very encouraging preliminary in vivo results, the establishment of a collaboration with the HUS Comprehensive Cancer Center at Helsinki, Finland for the optimization of Defence's Accum-T-DM1...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
